Roger Lo, M.D., Ph.D., F.A.A.D.
Dr. Roger Lo is Professor and Associate Chief of Medicine/Dermatology and Program Director of the Dermatology STAR Residency at UCLA’s David Geffen School of Medicine. He earned his BS in Biology (Honors and Distinction, 1994, Stanford University) and his MD-PhD degrees from the Tri-institutional (Weill Cornell, MSKCC, and Rockefeller) Program in 2002. After residency and postdoc training at UCLA, he joined the faculty in 2008. Work from his group has been recognized for providing the major scientific rationale toward the use of inhibitors of BRAF and MEK in combination to effectively treat melanoma – a therapeutic approach that is now globally considered the standard of care. Studies from his group have provided rationale for additional clinical trials and foundational knowledge on the roles of tumor heterogeneity, non-genomic processes, and the tumor microenvironment in determining clinical responses to mutation/immune-targeted therapies. His work has been published in Nature, New England Journal of Medicine, Cancer Discovery, Cancer Cell, and Cell. Dr. Lo was elected to American Society for Clinical Investigation in 2012 and American Dermatological Association in 2015. He received the 33rd Annual Award for Outstanding Achievement in Cancer Research from the American Association for Cancer Research (AACR) (2013) and the inaugural AACR-Waun Ki Hong Award for Outstanding Achievement in Cancer Research (2017). He served on the Editorial Board of the AACR journal Cancer Discovery. In 2019, Dr. Lo was named a Highly Cited Researcher (HCR) as reported by ClarivateAnalytics (formerly Thomson Reuters), which selects HCRs for exceptional research performance as determined by production of multiple highly cited papers that rank in the top 1% by citations for 21 fields and during the decade from 2008 to 2018. Dr. Lo chairs the Education Program of the 2021 AACR Annual Meeting.